Metastatic Non Small Cell Lung Cancer clinical trials

Explore recruiting metastatic non small cell lung cancer clinical trials.

Recruiting metastatic non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Open-label Randomized Study of MORAb-202 (Farletuzumab Ecteribulin), a Folate Receptor Alpha-targeting Antibody-Drug Conjugate, in Participants with Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC) After Progression on Prior Therapies

Spain, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II Study of SKB264 as Monotherapy or as Combination Therapy in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer

Spain, Romania

Therapeutic exploratory (Phase II) EU CTIS Study details

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Poland, Netherlands, Hungary, Bulgaria, Estonia, Ireland +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase 2 Study of Zelenectide Pevedotin in Participants with Previously-Treated NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer

Italy, Spain, France, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

PHASE 3 RANDOMIZED STUDY OF DS-1062A VERSUS DOCETAXEL IN PREVIOUSLY TREATED ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH OR WITHOUT ACTIONABLE GENOMIC ALTERATIONS (TROPION-LUNG01)

Spain, Poland, France, Belgium, Italy, Netherlands +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)

Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Metastatic Non Small Cell Lung Cancer trials by city

Metastatic Non Small Cell Lung Cancer in Toronto Metastatic Non Small Cell Lung Cancer in Vancouver Metastatic Non Small Cell Lung Cancer in Montreal Metastatic Non Small Cell Lung Cancer in Calgary Metastatic Non Small Cell Lung Cancer in Edmonton Metastatic Non Small Cell Lung Cancer in Ottawa Metastatic Non Small Cell Lung Cancer in Winnipeg Metastatic Non Small Cell Lung Cancer in Quebec City Metastatic Non Small Cell Lung Cancer in Hamilton Metastatic Non Small Cell Lung Cancer in Kitchener Metastatic Non Small Cell Lung Cancer in London Metastatic Non Small Cell Lung Cancer in Halifax Metastatic Non Small Cell Lung Cancer in New York Metastatic Non Small Cell Lung Cancer in Los Angeles Metastatic Non Small Cell Lung Cancer in Chicago Metastatic Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease